Yep this mgmt. team has shown a severe lack of vision and foresight and adaptability over the past 4 years running now...and ever since last july's adcom disaster seem to have completely gone off the rails.
There's simply no excuse for the lack of any progress and advancement from their totally stagnant pipeline whatsoever over the past 9 full months coming out of the adcom disaster.
What happened to the vaunted/promised PODRAS POC human trials? They told the market those trials would occur in the back half of 2017 and yet here we are in April 2018 and we continue to hear nothing!
What happened to CAT 2 & 3 oral and nasal Rexista HAP studies? They promised those studies way back in August 2017 yet here we are less than a week away from May 2018 and we continue to hear absolutely nothing!
Where's the foresight, planning and quick thinking/moving to at least start attempting to extract some sort of inherent value from their stagnant pipeline?
At this point their entire generics division and pipeline have resulted in a great big drain on this company's resources with little to no relevant revenue results provided.
In fact, their generics division and pipeline has got so bad that it's almost to the point that they may as well sell it off for whatever they can get and start focusing 100% of their energies on their stagnant PODRAS platform and their stagnant Rexista and Regabatin NDA candidates...and maybe get around to filing the other 20 opioid based NDA's they've claimed to be waiting to file with the FDA for several years now!
News 
Market Data 
Discover 
